Michael Vala, PharmD

Michael Vala, PharmD, is a PGY-2 infectious diseases pharmacy resident at Beth Israel Deaconess Medical Center in Boston, Massachusetts, who is interested in transplant infectious diseases and mycobacterial infections.

Articles by Michael Vala, PharmD

Is Renal-Adjusted Ceftazidime/Avibactam in Patients With KPC-Producing Klebsiella Pneumoniae Bloodstream Infection Associated With Increased Mortality?

ByMichael Vala, PharmD

April 23rd 2025

Do We Have New Data for Optimal Treatments of Candida-Related Prosthetic Joint Infections?

ByYingsi(Vincy) Fang, PharmD, BSC,Michael Vala, PharmD

January 14th 2025

The choice between debridement and implant exchange affects treatment outcomes for Candida-related prosthetic joint infections, highlighting the need for standardized guidelines and further research.

Michael Vala, PharmD

Articles by Michael Vala, PharmD

Is Renal-Adjusted Ceftazidime/Avibactam in Patients With KPC-Producing Klebsiella Pneumoniae Bloodstream Infection Associated With Increased Mortality?

Do We Have New Data for Optimal Treatments of Candida-Related Prosthetic Joint Infections?

Latest Updated Articles

Trending on Contagion Live

New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine

Oral Carbapenem Tebipenem HBr Demonstrates Non-Inferiority to IV Therapy in Phase III PIVOT-PO Trial

Introducing Cefiderocol Earlier in Difficult-to-Treat-Infections

Developing a COVID-19 Vaccine Alternative

Lori Handy, MD, MSCE, Discusses New Era of Dynamic, Trust-Based Health Communication